David Calhoun to Incidence
This is a "connection" page, showing publications David Calhoun has written about Incidence.
Connection Strength
0.512
-
Tolosa JN, Calhoun DA. Maternal and neonatal demographics of macrosomic infants admitted to the neonatal intensive care unit. J Perinatol. 2017 12; 37(12):1292-1296.
Score: 0.122
-
Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
Score: 0.096
-
Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008 Dec; 10(6):496-503.
Score: 0.067
-
Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl. 2002; 91(438):98-103.
Score: 0.041
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Olmos LF, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. Hypertens Res. 2019 11; 42(11):1708-1715.
Score: 0.035
-
Thomas SJ, Booth JN, Dai C, Li X, Allen N, Calhoun D, Carson AP, Gidding S, Lewis CE, Shikany JM, Shimbo D, Sidney S, Muntner P. Cumulative Incidence of Hypertension by 55?Years of Age in Blacks and Whites: The CARDIA Study. J Am Heart Assoc. 2018 07 11; 7(14).
Score: 0.032
-
Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
Score: 0.031
-
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
Score: 0.025
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
Score: 0.024
-
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
Score: 0.021
-
Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, Kim Y, Jacobs DR, Kiefe CI. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011 Jan; 57(1):39-47.
Score: 0.019